Drug Trial News

RSS

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

EDAP TMS SA, the global leader in therapeutic ultrasound, today reported favorable clinical outcomes for patients treated with Ablatherm-HIFU.

9 Sep 2010

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

Nevirapine is widely used to help prevent mother-to-child transmission of the HIV virus. In cases where the infants are nonetheless infected with HIV virus at birth, the standard treatment is to use protease inhibitors (PI) to reduce the amount of virus in their bloodstream. A new study involving 195 infants in South Africa found that children who were treated with PI and then switched to nevirapine were more likely to maintain virus below the detection threshold of the test than infants who continued to receive PI.

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.

9 Sep 2010

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

GE Healthcare announced today that results from its multicenter phase 2 study of flutemetamol were published in the September issue of Annals of Neurology. Flutemetamol is an investigational positron emission tomography (PET) imaging agent being developed by GE Healthcare, in the field of brain imaging.

9 Sep 2010

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.

8 Sep 2010

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.

8 Sep 2010

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

Emergent BioSolutions Inc. announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent's fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.

8 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Plexxikon today announced publication of key data in this week's edition of Nature demonstrating that the high degree of selectivity of PLX4032 (RG7204) enables substantial RAF/MEK/ERK pathway inhibition, which may be necessary to achieve significant tumor shrinkage and clinical response in patients with BRAF mutant melanoma.

8 Sep 2010

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Vertex Pharmaceuticals Incorporated today announced that 65% of people overall achieved a sustained viral response (SVR or viral cure) with a telaprevir-based regimen in the pivotal Phase 3 REALIZE study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.

8 Sep 2010

Gemcitabine does not improve survival compared with fluorouracil plus folinic acid in resected pancreatic cancer

Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a study in the September 8 issue of JAMA.

8 Sep 2010

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Octapharma AG today announced the imminent start of the biggest ever study of an intravenous immunoglobulin preparation (IVIG) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

8 Sep 2010

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Onyx Pharmaceuticals, Inc. today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib and ONX 0912. Under the terms of the agreement, Ono has exclusive rights to develop and commercialize both compounds for all oncology indications in Japan.

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

ESPAC-3 trial shows promising results to prevent pancreatic cancer

A major international trial has shown a commonly used chemotherapy drug is as effective at helping prevent pancreatic cancer returning after surgery as the more expensive standard chemotherapy treatment, reveals a study published in the Journal of the American Medical Association today (Wednesday).

8 Sep 2010

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.

8 Sep 2010

Methylphenidate facilitates recovery from drug addiction

A brain-scanning study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, conducted with collaborators from Stony Brook University, reveals that an oral dose of methylphenidate, commonly known as Ritalin, improves impaired brain function and enhances cognitive performance in people who are addicted to cocaine.

7 Sep 2010

Drug Trial News

EDAP reports clinical outcomes of Ablatherm-HIFU treatment in prostate cancer patients

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-infected children

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

GE Healthcare's flutemetamol phase 2 study results published in 'Annals of Neurology'

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

PLX4032 trial shows high degree of selectivity to achieve tumor shrinkage

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Gemcitabine does not improve survival compared with fluorouracil plus folinic acid in resected pancreatic cancer

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

ESPAC-3 trial shows promising results to prevent pancreatic cancer

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Methylphenidate facilitates recovery from drug addiction

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News